Document Type : Original Article
Authors
1 Department of Health Service Management, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Pharmacoeconomics and Pharma Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Objective: The aim of this study was to review the current methods of pharmaceutical
purchasing by Iranian insurance organizations within the World Bank conceptual framework
model so as to provide applicable pharmaceutical resource allocation and purchasing (RAP)
arrangements in Iran.
Methods: This qualitative study was conducted through a qualitative document
analysis (QDA), applying the four‑step Scott method in document selection, and conducting
20 semi‑structured interviews using a triangulation method. Furthermore, the data were
analyzed applying five steps framework analysis using Atlas‑ti software.
Findings: The QDA showed that the purchasers face many structural, financing, payment,
delivery and service procurement and purchasing challenges. Moreover, the findings of
interviews are provided in three sections including demand‑side, supply‑side and price and
incentive regime.
Conclusion: Localizing RAP arrangements as a World Bank Framework in a developing
country like Iran considers the following as the prerequisite for implementing strategic
purchasing in pharmaceutical sector: The improvement of accessibility, subsidiary mechanisms,
reimbursement of new drugs, rational use, uniform pharmacopeia, best supplier selection,
reduction of induced demand and moral hazard, payment reform. It is obvious that for Iran,
these customized aspects are more various and detailed than those proposed in a World
Bank model for developing countries.
Keywords
- MehralianG, RangchianM, JavadiA, Peiravian F. Investigation
on barriers to pharmaceutical care in community pharmacies:
A structural equation model. Int J Clin Pharm 2014;36:1087-94.
2. Abachizade K, Bastani P, Abolhalaj M. A comprehensive
analysis of drug system money map in Islamic Republic of
Iran. J Econ Sustain Dev 2013;4:158‑64.
3. LuY, Hernandez P, Abegunde D, Edejer T. The world medicine
situation 2011. Medicine Prices, Availability and affordability.
3rd ed. Geneva: World Health Organization; 2011. p. 3‑5.
4. Winkelmann R. Co-payments for prescription drugs and the
demand for doctor visits – evidence from a natural experiment.
Health Econ 2004;13:1081-9.
5. PrekerAS, LangenbrunnerJC. Spending Wisely Buying Health
Services for the Poor. 1st ed. Washington DC: The World Bank
Publisher; 2005. p. 18‑22.
6. Abolhalaj M, Abachizade K, Bastani P, Ramezanian M,
Tamizkar N. Production and consumption financial process of
drugs in Iranian healthcare market. Dev Cty Stud 2013;3:187‑91.
7. Policy Making Council of Ministry of Health and Medical
Education (Iran). Islamic Republic of Iran Health in the Fifth
Economical, Social and Cultural Plan. The Institute, Tehran;
2009. p. 21‑7. Available from: http://www.behdasht.gov.ir/.
[Last accessed on 2013 Aug 13].
8. Noori M. The Report of 5‑years Performance of Iranian Social
Treatment Security, Report of Iranian Health Sector Study, the
Investigation of Secondary Information 2008. p. 8-16. - 9. Pouragha B, Pourreza A, Heydari H. Effect of access and out
of pocket payment on GP’s visit utilization: A data panel study
among individuals covered by social security organization.
Hakim Res J 2011;15:101‑11.
10. World Health Organization. The World Health Report 2000:
Health systems: Improving performance. Geneva: World
Health Organization; 2000. p. 85‑93.
11. Ferenz M, NilsenK, Walters G. Research Methods in
Management. 2nd ed. Canada: SAGE Publication; 2009. p. 54‑60.
12. Jafari M, RashidianA, Abolhasani F, Mohammad K, Yazdani S,
Parkerton P, et al. Space or no space for managing public
hospitals; a qualitative study of hospital autonomy in Iran.
Int J Health Plann Manage 2011;26:e121-137.
13. Mehralian G, Rangchian M, Rasekh HR. Client priorities and
satisfaction with community pharmacies: The situation in
Tehran. Int J Clin Pharm 2014;36:707‑15.
14. Mehralian GH, Yousefi N, Hashemian F. Knowledge, attitude
and practice of pharmacists regarding dietary supplements:
A community pharmacy-based survey in Tehran. Iran J Pharm
Res 2014;13:1455‑63.
15. Khakmardani AH. Determining a Model for Strategic
Purchasing of Outpatient Health Care Services, World Health
Organization, Final Report APW: 07/38; 2007. p. 52‑65.
16. Rosenblatt RA, Andrilla CH, Curtin T, Hart LG. Shortages of
medical personnel at community health centers: Implications
for planned expansion. JAMA 2006;295:1042‑9.
17. Darbooy SH, Hoseini SA, Ahmadi B, editors. Pharmaceutical
Management in Family Physician and Rural Insurance.
Proceedings of the 1st National Congress of Management and
Pharma Economics 13‑15 June, 2012; Tehran, Iran.
18. Zarenezhad F, Mehralian GH, Rajabzadeh Ghatari A.
Developing a model for agile pharmaceutical distribution:
Evidence from Iran. J Basic Appl Sci Res 2013;3:161-72.
19. Levison L. Policy and Programming Options for Reducing
the Procurement Costs of Essential Medicines in Developing
Countries [Concentration paper]. Department of International
Health, School of Public Health, Boston University; 2003. p. 75‑82.
20. Al Serouri AW, Balabanova D, Hibshi SA. Cost Sharing for
Primary Health Care. Lessons from Yemen [working papers].
Oxfam University; 2002. p. 41-9.
21. GholiZadeh A, Vahid Dastjerdi AA, editors. Survey on
Effective Cultural Elements on Drug Use. Proceedings of the
1st National Congress of Management and Pharma Economics
13‑15 June, 2012; Tehran, Iran.
22. Quintal C, Mendes P. Underuse of generic medicines in
Portugal: An empirical study on the perceptions and attitudes
of patients and pharmacists. Health Policy 2012;104:61-8.
23. Holloway KA, Gautam BR, Reeves BC. The effects of different
kinds of user fees on prescribing quality in rural Nepal. J Clin
Epidemiol 2001;54:1065‑71.
24. Preker AS, Langenbrunner JC, Belli PC. Public Ends Private
Means Strategic Purchasing of Health Services. 1st ed.
Washington DC: The World Bank Publisher; 2007. p. 11‑25.
25. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A,
Reynier JP. Ongoing pharmaceutical reforms in France:
Implications for key stakeholder groups. Appl Health Econ
Health Policy 2010;8:7-24.
26. Thomson S, Busse R, Crivelli L, van de Ven W, Van de
Voorde C. Statutory health insurance competition in Europe:
A four‑country comparison. Health Policy 2013;109:209‑25.
)